European Pharmaceutical Review

DECEMBER 2, 2022

Vaccines Europe has unveiled its first pipeline review of its 15 members companies, with 100 vaccine candidates as of July 2022. . The data indicated 46 percent of the vaccine candidates target infections that do not have an available vaccine. Establish digital vaccination registries to improve vaccination coverage rates.

Vaccines 98

Vaccines Immunization 98

pharmaphorum

MAY 9, 2022

Johnson & Johnson has halved the size of its collaboration with Bavarian Nordic on vaccine development, jettisoning its stake in shots targeting human papillomavirus (HPV) and hepatitis B virus (HBV). The aim of both alliances was to study MVA-BN in a prime-boost vaccine regimen with Janssen’s own AdVac vaccine technology.

Vaccines 52

Vaccines 52

pharmaphorum

OCTOBER 26, 2020

Strategies include different options focused on health maintenance, such as vaccination programmes, smoking cessation services, support for physical activity, and access to technologies that support early detection of diseases. How could payer views change by 2030? Understanding payer views of preventive care.

Vaccines 130

Vaccines 130

Pharmacy Times

JUNE 12, 2025

The introduction of the human papillomavirus (HPV) vaccine marked a major turning point, contributing to nearly a 50% reduction in incidence rates and a 70% decrease in mortality since the 1950s. It is more sensitive in identifying high-risk HPV types, enabling earlier detection of potential cancer risk.

Vaccines 65

Vaccines Immunization Compounding Pharmacies FDA 65

PharmaVoice

JUNE 27, 2025

Now, the WHO’s aggressive goal to “ end HIV/AIDS ” by 2030 could be hampered by dramatic reductions in U.S. A long-time leader in vaccines, the U.K. million Americans are infected with HIV, but the disease disproportionately impacts people in sub-Saharan Africa. While Enhertu pulled in about $3.8

FDA 130

FDA Vaccines Packaging Dosage 130

European Pharmaceutical Review

OCTOBER 4, 2023

The World Health Organization ( WHO ) has recommended a new vaccine, R21/Matrix-M, to prevent malaria in children. The R21 vaccine is the second malaria vaccine recommended by WHO. This follows the WHO’s recommendation of the RTS,S/AS01 vaccine for the disease in 2021.

Vaccines 111

Vaccines 111

pharmaphorum

JUNE 29, 2022

Already competing to bring the first vaccine against respiratory syncytial virus (RSV) to market, Pfizer and GSK are also fighting a patent infringement battle in the courts. Pfizer’s RSVpreF vaccine is in hot pursuit of GSK’s shot, with results due to be reported very soon from the phase 3 RENOIR trial in older adults.

Vaccines 102

Vaccines 102

Pharmaceutical Technology

JUNE 26, 2025

The UK has confirmed its support for global vaccination by pledging £1.25bn to global vaccine group Gavi while the US will halt funding to the international organisation. The group had set a fundraising target of $11.9bn for its 2026-2030 budget. Credit: speedshutter Photography via Shutterstock.

Vaccines 59

Vaccines Packaging Communication Hospitals 59

European Pharmaceutical Review

OCTOBER 18, 2022

billion by 2030, according to a market report. However, during the second half, the surge in demand for vaccines to fight the coronavirus enhanced the industry’s need for raw materials and product intermediates of API molecules. billion by 2030 appeared first on European Pharmaceutical Review. billion in 2022 to $14.65

Dosage 105

Dosage Vaccines 105

Pharmaceutical Technology

JULY 2, 2025

How will RFK Jr’s American dream for vaccines play out? The projected growth of the cell and gene therapy market GlobalData estimates that the cell and gene therapy market will achieve global sales of $76.03bn by 2030, up from $5.88bn in 2023, with a compound annual growth rate (CAGR) of 44% over the seven years analysed.

Packaging 52

Packaging Compounding Communication FDA 52

European Pharmaceutical Review

NOVEMBER 7, 2024

percent between 2025 and 2030. Increasing demand for biopharmaceuticals, “including therapeutic proteins and vaccines, drives the use of rocking bioreactors in cell culture processes”, the reported explained. Key companies profiled in the single-use technology rocking bioreactor market report included Thermo Fisher Scientific Inc.,

Compounding 52

Compounding Vaccines 52

Pharmaceutical Technology

MAY 25, 2023

A new vaccine developed by the Serum Institute of India to fight meningococcal disease could help eliminate meningitis across Africa. The results from a trial, published in The New England Journal of Medicine , found the vaccine was associated with a strong immune response and good safety profile. percentage points (96% CI, −0.3

Vaccines 78

Vaccines Immunization 78

European Pharmaceutical Review

NOVEMBER 13, 2024

Lenacapavir for PrEP could provide an important alternative to existing preventative medications that require more frequent dosing, and could help transform the HIV prevention landscape by addressing a range of unmet needs for individuals who need or want PrEP globally,” Ogbuagu added.

Vaccines 98

Vaccines FDA 98

Pharmacy Times

JUNE 18, 2025

The Healthy People 2030 initiative addresses structural health care inequalities and implements programs to ameliorate SDOH. Healthy People 2030. Each unique set of economic, educational, social, and environmental circumstances significantly affects their quality of life and health. REFERENCES 1. Social determinants of health.

Immunization 65

Immunization Compounding Pharmacies Hospitals Chemotherapy 65

Pharmacy Times

JUNE 19, 2025

With annual growth projected at 36% through 2030 and 10 to 20 new approvals expected each year, oncology pharmacists are likely to encounter these therapies more frequently across care settings. 2-4 In the United States, the FDA had approved 44 cell therapy products as of March 6, 2025.

Compounding 65

Compounding Compounding Pharmacies FDA Immunization 65

Pharmacy Times

JUNE 9, 2025

2019;380:2020-2030. Global Initiative for Asthma. Accessed June 9, 2025. Beasley R, Holliday M, Reddell HK, et al. Controlled trial of budesonide-formoterol as needed for mild asthma. N Engl J Med.

Compounding Pharmacies 73

Compounding Pharmacies Hospitals Immunization Chemotherapy 73

European Pharmaceutical Review

AUGUST 3, 2022

To fill the divide, the Joint United Nations Programme on HIV and AIDS (UNAIDS) , the United Nations Children’s Fund (UNICEF), the World Health Organization (WHO) and partners have brought together a global alliance to ensure that no child living with HIV is denied treatment by 2030 – and to prevent new infant HIV infections.

Vaccines 105

Vaccines 105

PharmTech

JULY 4, 2025

Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines Feliza Mirasol April 30th 2024 Podcast In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.

Dosage 59

Dosage FDA Vaccines Pharmaceutical Companies 59

European Pharmaceutical Review

SEPTEMBER 7, 2022

billion market by 2030, growing from a 2020 value of around $2.4 New types of drugs, such as oral vaccines, will also be formulated as capsules. Insights on the Empty Capsules Global Market to 2030 – Featuring ACG Worldwide, Bright Pharma Caps and Lonza Among Others [Internet]. About the author. GlobeNewswire News Room.

Dosage 124

Dosage Vaccines 124

European Pharmaceutical Review

AUGUST 21, 2023

billion by 2030 and grow at a CAGR of 3.84 percent from 2023 to 2030. The data stated that expansion of the market in emerging countries is due to factors such as the rising success rate of RNA-based COVID-19 vaccines, regulatory approval, as well as demand for personalised medicines.

Vaccines 98

Vaccines 98

pharmaphorum

JANUARY 15, 2021

Now, speaking to him as the first vaccines are deployed in the UK, he highlights the importance of GSK’s employees and culture to the future of the company post-COVID. With the new goals, GSK aims to have a net zero impact on climate and a net positive impact on nature by 2030.

Vaccines 105

Vaccines 105

STAT

DECEMBER 13, 2024

Specifically, the amount spent on basic research, new treatments, vaccines, and diagnostics was $1.2 Yet this amounted to only one quarter of the $5 billion annual goal that was adopted last year at a United Nations High-Level Meeting on TB as part of a plan to end the epidemic by 2030. Meanwhile, the U.S.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Vaccines 98

Pharma Mirror

OCTOBER 28, 2021

Amsterdam, The second part of the 2021 CPhI Annual Report looks ahead to predict the pharma manufacturing, therapeutic and technology environment in 2030. The post CPhI Annual Report 2021: Short term reshoring the catalyst for longer term manufacturing innovations by 2030 appeared first on Pharma Mirror Magazine.

Vaccines 52

Vaccines 52

Pharmaceutical Technology

MARCH 31, 2023

The company will construct the new advanced mRNA facility, which is claimed to be Moderna’s first mRNA manufacturing facility in Africa and is expected to have the capacity to produce up to 500 million vaccine doses annually. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.

Vaccines 105

Vaccines 105

pharmaphorum

AUGUST 3, 2022

The fall reflects “COVID-19 related rates and severity of infections and hospitalisations, as well as the availability, uptake and effectiveness of vaccinations and alternative treatments for COVID-19,” said the company.

Vaccines 105

Vaccines 105

PharmTech

JULY 1, 2025

Recent Videos Related Content Hikma Pharmaceuticals Invests $1 Billion to Expand US Generic Drug Capabilities, Releases Sustainability Report Susan Haigney June 30th 2025 Article The company is expanding its US manufacturing and R&D capabilities with a $1 billion investment by 2030.

Dosage 45

Dosage Packaging Vaccines Pharmaceutical Companies 45

PharmTech

JUNE 30, 2025

Science laboratory test tubes, laboratory equipment | Image Credit: © BillionPhotos.com - © BillionPhotos.com - stock.adobe.com Hikma Pharmaceuticals USA announced on June 28, 2025 that it is investing $1 billion by 2030 to expand its generic-drug R&D and manufacturing capabilities in its Ohio and New Jersey, United States, facilities.

Dosage 59

Dosage Generic Medicine Vaccines 59

pharmaphorum

MARCH 31, 2021

An excellent example of this is COVID-19 vaccine trial data; press releases are eagerly followed in almost real-time by HCPs and the public alike. Q5: ‘Blue-sky thinking’: what will data dissemination look like in 2030? What are the associated challenges?

Communication 98

Communication Pharmaceutical Companies Pharmaceutical Companies Vaccines 98

Pharmaceutical Technology

JUNE 13, 2025

“The label expansion for Mavyret, coupled with the implementation of ‘test and treat’ models of care, serves as a tool to support the public health community in treating more patients and bringing us closer to achieving the global 2030 elimination goal.”

Labelling 52

Labelling FDA Communication Hospitals 52

pharmaphorum

JANUARY 24, 2023

Where medicines are biologics, such as vaccines, insulin, blood products, and numerous specialty medicines, failsafe cold chains will be necessary from manufacturer to patient. Wholesalers and pharmacies operate under regulations which define storage, supply, and service standards, and these come with energy requirements.

Pharmaceutical Companies 98

Pharmaceutical Companies Pharmaceutical Companies Vaccines 98

pharmaphorum

JUNE 1, 2022

Practical examples of this include healthcare professionals using VR to learn various medical procedures or for the technology to be used to teach broader society about public health issues, such as the importance of vaccination. When both ‘treatments’ were combined, the vaccination intention increased even further. The more you know.

Vaccines 145

Vaccines Immunization Hospitals Packaging 145

Fierce Pharma

OCTOBER 31, 2024

While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional fright surrounding another staple product took the spotlight during the co | Despite the China growth woes, Merck is still confident it can achieve its $11 billion sales goal for the HPV vaccine by 2030.

Vaccines 120

Vaccines 120

European Pharmaceutical Review

JANUARY 22, 2024

million by 2030, according to a report by ResearchAndMarkets. Between 2023 to 2030, this represents a CAGR of 15.13 As the expansion of the biopharmaceutical industry has continued, in 2022, increased demand for vaccine production enabled the Asia Pacific region to witness “significant growth”, with a CAGR of 15.32

Vaccines 52

Vaccines 52

European Pharmaceutical Review

MAY 21, 2025

The collaboration between BioNTech and the UK government focuses on three key areas: accelerating oncology clinical trials for BioNTechs investigational medicines investment to increase BioNTechs UK R&D footprint research into certain areas such as regenerative medicine and infectious disease vaccines.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies Vaccines 52

Pharmaceutical Technology

JUNE 27, 2022

The international agency had previously set a target of eliminating viral hepatitis by 2030. As such, a hepatitis C vaccine may yet be needed for elimination, since there are cohorts of patients who will not be reached, Foster said during the subsequent panel discussion.

Vaccines 105

Vaccines 105

Pharmaceutical Technology

MAY 22, 2023

billion) by 2030. There is a stark difference in favour of the UK biotech ecosystem in terms of expenses compared to the US biotech ecosystem, and specifically the New England region, says Mark Leuchtenberger, CEO of Oxford-based company SpyBiotech, a vaccine developer that plans to study a human cytomegalovirus infection vaccine in H2 2023.

Vaccines 111

Vaccines Compounding Communication 111

PharmaShots

APRIL 11, 2023

Bleeding after circumcision Bleeding after having shots, such as vaccinations. by 2030 at a CAGR of 6.9% Symptoms:1 Prolonged oozing after injuries, tooth extractions or surgery Hematoma Bruising Bleeding into the joints, mouth and gums Bleeding of the mouth and gums, and bleeding that is hard to stop after losing a tooth.

Immunization 64

Immunization Vaccines 64